BNOX logo

Bionomics Limited (BNOX) Company Overview

Profile

Full Name:

Neuphoria Therapeutics Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Australia

IPO:

December 16, 2021

Indexes:

Not included

Description:

Bionomics Limited (BNOX) is a biotechnology company focused on developing innovative therapies for central nervous system disorders and cancer. They leverage their proprietary drug discovery platform to create treatments aimed at improving patient outcomes in areas with significant unmet medical needs.

Events Calendar

Earnings

Next earnings date:

Nov 14, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Aug 25, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 24, 2024

Analyst ratings

Recent major analysts updates

Aug 1, 24 HC Wainwright & Co.
Buy
Jul 18, 24 HC Wainwright & Co.
Buy
Jun 12, 24 HC Wainwright & Co.
Buy
Mar 21, 24 HC Wainwright & Co.
Buy
Dec 7, 23 HC Wainwright & Co.
Buy
Sep 28, 23 Maxim Group
Buy
Sep 28, 23 HC Wainwright & Co.
Buy
Jun 16, 23 Maxim Group
Buy
Mar 10, 23 Evercore ISI Group
Outperform
Mar 9, 23 Loop Capital
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Bionomics Limited?
  • Does Bionomics Limited pay dividends?
  • What sector is Bionomics Limited in?
  • What industry is Bionomics Limited in?
  • What country is Bionomics Limited based in?
  • When did Bionomics Limited go public?
  • Is Bionomics Limited in the S&P 500?
  • Is Bionomics Limited in the NASDAQ 100?
  • Is Bionomics Limited in the Dow Jones?
  • When was Bionomics Limited's last earnings report?
  • When does Bionomics Limited report earnings?
  • Should I buy Bionomics Limited stock now?

What is the ticker symbol for Bionomics Limited?

The ticker symbol for Bionomics Limited is NASDAQ:BNOX

Does Bionomics Limited pay dividends?

No, Bionomics Limited does not pay dividends

What sector is Bionomics Limited in?

Bionomics Limited is in the Healthcare sector

What industry is Bionomics Limited in?

Bionomics Limited is in the Biotechnology industry

What country is Bionomics Limited based in?

Bionomics Limited is headquartered in Australia

When did Bionomics Limited go public?

Bionomics Limited's initial public offering (IPO) was on December 16, 2021

Is Bionomics Limited in the S&P 500?

No, Bionomics Limited is not included in the S&P 500 index

Is Bionomics Limited in the NASDAQ 100?

No, Bionomics Limited is not included in the NASDAQ 100 index

Is Bionomics Limited in the Dow Jones?

No, Bionomics Limited is not included in the Dow Jones index

When was Bionomics Limited's last earnings report?

Bionomics Limited's most recent earnings report was on Nov 14, 2024

When does Bionomics Limited report earnings?

The next expected earnings date for Bionomics Limited is Nov 14, 2025

Should I buy Bionomics Limited stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions